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Summary
We have identified four mutations in each of the breast
cancer–susceptibility genes, BRCA1 and BRCA2, in
French Canadian breast cancer and breast/ovarian can-
cer families from Quebec. To identify founder effects,
we examined independently ascertained French Cana-
dian cancer families for the distribution of these eight
mutations. Mutations were found in 41 of 97 families.
Six of eight mutations were observed at least twice. The
BRCA1 C4446T mutation was the most common mu-
tation found, followed by the BRCA2 8765delAG mu-
tation. Together, these mutations were found in 28 of
41 families identified to have a mutation. The odds of
detection of any of the four BRCA1 mutations was
18.7# greater if one or more cases of ovarian cancer
were also present in the family. The odds of detection
of any of the four BRCA2 mutations was 5.3# greater
if there were at least five cases of breast cancer in the
family. Interestingly, the presence of a breast cancer case
!36 years of age was strongly predictive of the presence
of any of the eight mutations screened. Carriers of the
same mutation, from different families, shared similar
haplotypes, indicating that the mutant alleles were likely
to be identical by descent for a mutation in the founder
population. The identification of common BRCA1 and
BRCA2 mutations will facilitate carrier detection in
French Canadian breast cancer and breast/ovarian can-
cer families.
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Introduction
Germ-line mutations in the breast cancer–susceptibility
genes, BRCA1 and BRCA2, account for a large pro-
portion of hereditary breast cancer and breast/ovarian
cancer families. Screening for mutations has been ham-
pered by the large size of the BRCA1 and BRCA2 genes
(Miki et al. 1994; Wooster et al. 1995; Tavitgan et al.
1996), the frequent occurrence of unique mutations
(Breast Cancer Information Core database), and putative
“regulatory mutations” (Serova et al. 1996). However,
within defined ethnic groups, specific relatively frequent
mutations have been identified. Three founder mutations
have been identified in the Ashkenazi Jewish families
of eastern European ancestry (Friedman et al. 1995;
Struewing et al. 1995b; Tonin et al. 1995; Berman et al.
1996a, 1996b; Fitzgerald et al. 1996; Neuhausen et al.
1996a). Specific mutations also have been identified in
Icelandic, Swedish, British, Austrian, Dutch, Belgian,
Russian, and Hungarian families, and haplotype analysis
has provided evidence for founder effects in these ethnic
groups (Simard et al. 1994; Gayther et al. 1995; Shat-
tuck-Eidens et al. 1995; Johannesdottir et al. 1996; Jo-
hannsson et al. 1996; Wagner et al. 1996; Gayther et
al. 1997; Peelen et al. 1997; Ramus et al. 1997; Shattuck-
Eidens et al. 1997). The presence of founder effects, lead-
ing to reduced genetic heterogeneity, facilitates carrier
detection and genetic counseling, for certain well-defined
populations.
The French colonization of the province of Quebec
began in 1608 and continued until 1760 (Charbonneau
and Robert 1987). An estimated 8,000–10,000 French
migrants established themselves permanently in the
province (Charbonneau et al. 1987; Bouchard et al.
1988). Many of the hereditary disorders in the French
Canadian population show evidence of founder effects
(De Braekeleer and Dao 1994a, 1994b). For example,
five specific mutations in the low-density lipoprotein re-
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Table 1
Primer Sequences Used to Detect BRCA1 and BRCA2 Mutations in French Canadian Families
Gene
and Exon Mutation Effect
Annealing
Temperature Primer Pair Reference
BRCA1:
11 C2598A Thr826Lys 60 Forward: 5′-TAT GGC ACT CAG GAA AGT ATC TCG-3′ Simard et al. (1994)
Reverse: 5′-GCG CTT TGA AAC CTT GAA TGT AT-3′
11 2953del3C 950ter 55 Forward: 5′-TGC AGG CTT TCC TGT GGT TG-3′ Durocher et al. (1996)
Reverse: 5′-GGC TAA TTG TGC TCA CTG TAC TTG G-3′
11 3768insA 1218ter 57 Forward: 5′-GAG TCC TAG CCC TTT CAC CCA TAC-3′ This study
Reverse: 5′-GTG ATG TTC CTG AGA TGC CTT TG-3′
13 C4446T Arg1443ter 55 Forward: 5′-AAT GGA AAG CTT CTC AAA GTA-3′ This study
Reverse: 5′-ATG TTG GAG CTA GGT CCT TAC-3′
BRCA2:
11 2816insA 880ter 55 Forward: 5′-CCC ATG GAA AAG AAT CAA GAT G-3′ This study
Reverse: 5′-GTT CCT TAG TAT TCC TAA AGC-3′
11 G6085T Glu1953ter 55 Forward: 5′-AAG TGA AAG ACA TAT TTA CAG ACA G-3′ This study
Reverse: 5′-TAT GAA GCT TCC CTA TAC T-3′
11 6503delTT 2099ter 55 Forward: 5′-AAG TAA CGA ACA TTC AGA CC-3′ This study
Reverse: 5′-CTG GGT TTC TCT TAT CAA CAG CA-3′
20 8765delAG 2867ter 55 Forward: 5′-CAC TGT GCC TGG CCT GAT AC-3′ Phelan et al. (1996)
Reverse: 5′-AGT CTC TAA GAC TTT GTT CTC-3′
ceptor gene account for 76% of familial hypercholes-
terolemia (Davignon and Roy 1993). Founder effects
also have been described for b-thalassemia (De Brae-
keleer and Dao 1993), cytochrome C oxidase deficiency
(Morin et al. 1993), cystic fibrosis (Rozen et al. 1992),
pseudo vitamin D–deficiency rickets (Labuda et al.
1996), oculopharyngeal muscular dystrophy (Brais et al.
1995; Stajich et al. 1996), a severe form of peripheral
neuropathy and agenesis of the corpus callosum (Ca-
saubon et al. 1996), and autosomal recessive spastic
ataxia of Charlevoix-Saguenay (A. Richter, J. Rioux, J.-
P. Bouchard, J. Mercier, J. Mathieu, J. Poirier, D. Julien,
G. Gyapay, J. Weissenbach, T. J. Hudson, K. Morgan,
and S. B. Melanc¸on, unpublished data). We have iden-
tified four mutations in each of the breast cancer–
susceptibility genes, in French Canadian breast cancer
and breast/ovarian cancer families; three mutations have
been reported elsewhere (Simard et al. 1994; Durocher
et al. 1996; Phelan et al. 1996), and five additional mu-
tations are reported in this article. Given the expectation
of a founder effect, we examined independently ascer-
tained French Canadian breast cancer and breast/ovar-
ian cancer families for the distribution of these eight
mutations and associated haplotypes.
Families, Material, and Methods
Families
The index cases for mutation analysis represent 97
independently ascertained families that were recruited at
the following centers: the Hereditary Cancer Clinics of
McGill University, Montreal (35 families); the Breast
Clinic of the Centre Recherche CHUM Campus Hoˆtel
Dieu (29 families) and the Gynecology and Oncology
Clinic of Centre Recherche CHUM Campus Notre
Dame, Montreal (24 families); and the Hereditary Can-
cer Clinics affiliated with the University of Toronto, To-
ronto (9 families). Four families (179, 290, PG1940, and
hd13) have been described elsewhere (Simard et al. 1994;
Durocher et al. 1996; Phelan et al. 1996). Each family
had at least three cases of female breast cancer (diag-
nosed at !65 years of age), epithelial ovarian cancer, or
male breast cancer; and two affected individuals in each
family were either the first-, second-, or third-degree rel-
atives of the index case for the mutation analysis. The
families had cases of breast cancer only ( ) orn  48
breast and ovarian cancer ( ). Eight families hadn  49
one or more individuals with male breast cancer. The
cancer sites for at least three of the affected individuals
in each family were confirmed by a review of pathology
reports or death certificates. The index case was asked
about her French Canadian ancestry and the location of
settlement in Canada of her grandparents. Cancers at
other sites also were recorded and, when possible, con-
firmed in the same manner. The study was approved by
the appropriate institutional review boards, and in-
formed consent was obtained from each participating
individual.
The Panel of French Canadian BRCA1 and BRCA2
Mutations
The panel of BRCA1 and BRCA2 mutations used to
screen the index cases comprises three mutations that
have been reported elsewhere (Simard et al. 1994; Du-
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rocher et al. 1996; Phelan et al. 1996) and five additional
mutations not reported previously in French Canadian
families (table 1). The BRCA1 C4446T mutation was
identified in family 482 by routine screening for muta-
tions, by use of SSCP analysis, as described below. The
mutations 3768insA and 6503delTT were identified in
families W9072 and W98074, respectively, by use of a
protein-truncation test (PTT) assay of exon 11 for
BRCA1 and of exons 10 and 11 for BRCA2, essentially
as described by Hogervost et al. (1995). The primer se-
quences used in the PTT assays were obtained from the
Breast Cancer Information Core database. PTT was per-
formed by use of the TNT reticulocyte lysate system
(Promega), by incorporation of 35S- methionine/cysteine
(New England Nuclear) for protein detection. The
BRCA1 2816insA and BRCA2 G6085T mutations were
identified in families 107 and 787, respectively, by use
of the SSCP assay described by Phelan et al. (1996).
Screening for the Panel of French Canadian BRCA1
and BRCA2 Mutations
The primers used to detect the mutations are given in
table 1. PCR was performed in 12.5-ml volumes con-
taining 50 ng genomic DNA; 1# PCR buffer (Phar-
macia); 200 mM each of dCTP, dGTP, and dTTP; 10
mM dATP; 50 pmol of each primer; 0.75 mCi 35S-dATP;
and 0.5 U Taq DNA polymerase (Pharmacia). The re-
actions were amplified in a Perkin-Elmer 6900 thermal
cycler, for a total of 35 cycles of 95C for 30 s, annealing
at the optimal temperature for each primer pair for 30
s (table 1), and 72C for 30 s. The PCR products were
diluted 10-fold with loading buffer (90% formamide;
10 mM EDTA, pH 8.0; 0.05% bromophenol blue; and
0.05% xylene cyanol) and were denatured at 95C for
5 min, and then 5 ml was loaded on a 6% polyacrylamide
gel containing 5% glycerol. The samples were electro-
phoresed at 2 W constant power, at room temperature
(for the detection of the BRCA2 mutations 2816insA
and 8765delAG), or at 25 W constant power, at 4C
(for the detection of all BRCA1 mutations and BRCA2
mutations G6085T and 6503delTT); were transferred
to Whatman paper and dried at 80C on a vacuum gel
drier; and then were autoradiographed (Hyperfilm MP,
Amersham) for 12–72 h. Samples that displayed a band
shift, by SSCP analysis, were PCR amplified with the
appropriate SSCP primer set, and the PCR products were
gel purified and sequenced by use of a U.S. Biochemical
PCR product-sequencing kit, in accordance with the
manufacturer’s instructions.
Genotyping of 13q and 17q Markers
Polymorphic microsatellite repeat markers spanning
the BRCA1 locus (D17S855, D17S1322, D17S1323,
D17S1327, and D17S1326) (Neuhausen et al. 1996b)
and the BRCA2 locus (D13S260, D13S1698,
D13S1699, and D13S171) (Couch et al. 1996) were
used for haplotype analysis of families identified with
mutations. The PCR conditions were as described above
for the SSCP analysis, using the annealing temperatures
described for the BRCA1 (Neuhausen et al. 1996b) and
BRCA2 (Couch et al. 1996) markers. PCR products
were electrophoresed on 5% acrylamide gels and were
visualized as described above. The disease allele–
associated haplotype was deduced by inspection of seg-
regating genotypes in the families.
Results
Mutation Analysis
One of eight BRCA1 or BRCA2 mutations was iden-
tified in 41 of 97 French Canadian breast and breast/
ovarian cancer families (table 2). Six of the eight mu-
tations were observed in more than one family. The
BRCA1 C4446T and BRCA2 8765delAG mutations
were found frequently. The BRCA1 C2598A missense
mutation, first reported in family 179 (Simard et al.
1994), was not found in the other families. Seven of the
eight mutations are frameshift mutations, which are pre-
dicted to result in premature translation termination and
the production of truncated proteins (table 1). The
C2598A mutation, which was not detected in 86 French
Canadian control individuals (Simard et al. 1994), is
predicted to result in the amino acid substitution of thre-
onine to lysine at codon 826. Because we were not able
to determine whether this mutation segregates with
breast cancer in family 179, the functional significance
of this variant currently is unknown.
Haplotype Analysis
Haplotype analysis using polymorphic markers span-
ning the BRCA1 and BRCA2 loci was performed on
index cases and, when possible, on additional family
members, to determine whether carriers from different
families harbored the same mutation identical by de-
scent. Families with the same BRCA1 mutation shared
a common haplotype or a genotype compatible with a
shared haplotype (table 3). The haplotype associated
with each of the common BRCA1 mutations is unique
for that mutation. Although only one family has been
shown to carry C2598A, the genotype of the carrier of
this mutation also is distinguishable from the haplotypes
of the carriers of the common BRCA1 mutations. We
were not able to phase all carriers of 8765delAG, but
four haplotypes were observed in six independently as-
certained families identified with this mutation, all shar-
ing an allele of the same size for markers D13S1698 and
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Table 2
Phenotypes of French Canadian Families with BRCA1 and BRCA2 Mutations
GENE AND
FAMILY MUTATION
NO. OF CASES OF CANCER
OTHER CANCER(S)
Female Breast
Male
Breast
Ovarian
(Ovarian
and Breast)
At Age
X50 Years
(Bilateral)
At Age
150 Years
(Bilateral)
BRCA1:
179 C2598A 3 1 3 Kidney, skin
290 2953del3C 2 (1) 2 1 Kidney,a liver
486 2953del3C 8 (2) 2 4 (2) Bladder, colon, fallopian tube, kidney, leukemia,
lymphoma, lung, prostate, throat
869 2953del3C 1 3 Brain, lung, lymphoma
dp4 2953del3C 2 3 Colon, prostate, lung
W9072 3768insA 5 1 (1) 3
W1008A 3768insA 2 (2) 1 Stomach
151 C4446T 5 (2) 1 (1) Colon
214 C4446T 3 (2) Lung, papillary thyroid carcinomaa
252 C4446T 2 2 1 Cervical
307 C4446T 1 2 2 Brain, leukemia
476 C4446T 2 2 4 Larynx, pancreas
482 C4446T 3 1
547 C4446T 2 1 1 (1) Lung, sarcoma
650 C4446T 3 1 Cervical, colon, neuroblastoma
717 C4446T 4 2 (1) Skin
767 C4446T 3 1
813 C4446T 2 1 Throat
dp5 C4446T 3 3 1 2 Bone, colon, prostate, throat, stomach, testicular
hd92 C4446T 3 1 Colon, stomach
se2 C4446T 2 1 1 (1) Brain, vular
so26 C4446T 4 (1) 1
vn75 C4446T 7 (1) 1 1 Colon, lung, prostate, uterine
W9099 C4446T 2 (2) 1 Stomach
BRCA2:
107 2816insA 5 4 Colon, liver, skin (malignant melanoma)
hd74 2816insA 3 3 Bladder, lung, stomach
719 G6085T 5 1 Prostate
hd128 G6085T 4 (1) 2 Colon, skin
ml G6085T 3 (1)
W9074 6503delTT 5 Brain, colon, lymphoma
616 8765delAG 2 1 2 Bone
739 8765delAG 4 1 1 (1) Colon
825 8765delAG 5 3 Fallopian tube
853 8765delAG 3 Prostate
854 8765delAG 6 2 Stomach
hd13 8765delAG 3 1 Lung, pancreas, bone
hd86 8765delAG 5 (1) 1 Colon, leukemia, prostate
PG1940 8765delAG 12 (2) 9 2 Colon, duodenum, kidney, larynx, liver lung,
lymphoma, pancreas, prostate, vater
so28 8765delAG 4 1 (1) Esophagus, larynx, mouth, stomach
vn54 8765delAG 8 (2) 7 1 Colon, leukemia, lung, prostate, stomach,
throat, uterine
W10083 8765delAG 2 1 Brain
a Individual diagnosed with breast cancer and other cancer or cancer site named.
D13S1699 (table 4). The marker genotypes of all the
carriers of 8765delAG were consistent with the possi-
bility that they shared a common ancestry. At least two
different BRCA2 haplotypes, which differed at the prox-
imal flanking locus, D13S171, were observed for
G6085T (table 4). The carriers of 2816insA shared an
identical haplotype (table 4). The haplotypes of all three
common BRCA2 mutations are unique and differ
from the genotype determined for the carriers of the
6503delTT mutation observed in one family.
Tonin et al.: BRCA1 and BRCA2 Mutations in French Canadians 1345
Table 3
Haplotype Analysis of BRCA1 Mutant-Allele Carriers for Chromosome 17q
Markers
MUTATION
AND FAMILY
HAPLOTYPE, BY MARKERa
D17S855 D17S1322 D17S1323 D17S1327 D17S1326
C2598A:
179 5, 6 4, 5 2, 6 7, 12 10 10
2953del3C:
290 11 5 4 4 6, 3 7 7 9 9
486 3 5 4 4 5 3 12 7 2 9
869 5 5 4 4 3 3 6 7 10 9
dp4 6 5 2 4 3 3 3, 7 10 9
3768insA:
W9072 4 7 5 4 5 3 12, 5 4 10
W1008A 8, 7 5, 4 4, 3 15, 5 10 10
C4446T:
151 6 4 4 5 2 6 5 12 10 2
214 4 4 5 5 6 6 12 12 3, 2
252 4 4 5 5 6 6 12 12 4, 2
307 7 4 5 5 6 6 2 12 10 2
476 3 4 5 5 6 6 12 12 4 2
482 2 4 5 5 6 6 12 12 4 2
547 4 4 5 5 6 6 12 12 2 2
650 2, 4 5 5 6 6 12 12 2 2
717 1, 4 5 5 4, 6 12 12 2 2
so26 1, 4 5 5 6 6 12 12 2 2
vn75 1 4 5 5 6 6 12 12 2 2
767 6 4 4 5 3 6 1 12 10 2
813 4 4 3, 5 6 6 7, 12 10, 2
hd92 6, 4 5 5 6 6 12 12 2 2
se2 6 4 3 5 6 6 4 12 10 2
dp5 4 4 5 5 6 6 12 12 2 2
W9099 6 4 4, 5 4, 6 4, 12 10, 2
a Haplotypes segregating with BRCA1 mutant alleles are in boldface type, hap-
lotypes not segregating with the BRCA1 or BRCA2 mutant alleles are in italics, and
genotypes of unphased alleles are separated by a comma.
Phenotype of Families with Mutations
The phenotypes of the families with identified muta-
tions are shown in table 2, and the relative frequencies
of mutations in breast cancer and breast/ovarian cancer
families are shown in table 5. A greater proportion of
families with one or more cases of ovarian cancer were
found to carry a BRCA1mutation, rather than aBRCA2
mutation ( ). The odds of detecting one of fourP  .008
BRCA1 mutations was 18.7# greater if the proband
reported one or more cases of ovarian cancer in her
family ( ). Among the families with a muta-P ! .00001
tion, the presence of ovarian cancer also predicted which
of the two genes was found to harbor a mutation. The
odds for detection of a BRCA1 versus a BRCA2 mu-
tation was 26.4 when ovarian cancer was present
( ). It should be emphasized, however, that theP  .006
predictive models derived from these data are based
solely on the screening of four BRCA1 and four BRCA2
mutations.
Although our minimum inclusion criteria included at
least one case of breast cancer diagnosed at !65 years
of age, families harboring a BRCA2mutation contained,
on average, 6.7 cases of breast cancer, in contrast to
families harboring one of four BRCA1 mutations (3.9
cases/family) and to families found not to harbor any of
the eight mutations (3.7 cases/family). Among the 97
families, the odds of finding one of four BRCA2 mu-
tations was 5.3 if five or more cases of breast cancer
were present ( ). Among the subset of 41 fam-P  .003
ilies in which one of eight mutations was detected, the
odds of finding one of the fourBRCA2mutations (versus
one of the four BRCA1 mutations) was 5.4 if five or
more cases of breast cancer were present ( ).P  .02
The average age at breast cancer diagnosis was
younger in families harboring one of the four BRCA1
mutations (43.4 years) than in families not harboring a
BRCA1 mutation (48.9 years) ( ). The averageP  .0002
age at breast cancer diagnosis also was younger in fam-
ilies harboring one of the four BRCA2 mutations (46.8
years) than in families not harboring a BRCA2 muta-
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Table 4
Haplotype Analysis of BRCA2 Mutant-Allele Carriers for
Chromosome 13q Markers
MUTATION
AND
FAMILY
HAPLOTYPE, BY MARKERa
D13S260 D13S1698 D13S1699 D13S171
2816insA:
107 4 7 12 11 3 4 9 2
hd74 8 7 3 11 1 4 9 2
G6085T:
719 2 6 9 9 4, 3 9 9
hd128 7, 6 9 9 4 3 7 9
ml 7, 6 9 9 3 3 7 7
6503delTT:
W9074 7, 9 8, 9 3, 4 9 9
8765delAG:
616 9 4 9 11 4 3 9 9
739 7 4 9, 11 3 3 9 9
825 5, 4 9, 11 4, 3 2, 9
853 4 4 9, 11 4, 3 2, 9
854 8, 4 11 11 3 3 2, 9
hd13 4 7 12 11 3 3 2 9
hd86 4 7 11 11 3 3 2 2
PG1940 5 4 11 11 3 3 2 9
so28 7 7 9 11 3 3 9 9
vn54 7 4 9 11 4 3 2 9
W10083 4, 7 9, 11 3 3 7, 9
a Haplotypes segregating with a BRCA2 mutation are indicated
in boldface type, and genotypes of unphased alleles are separated
by a comma.
tion, but the difference was not significant ( ). InP  .17
Canada, the average age at diagnosis of ovarian cancer
is 56 years. The average age at diagnosis of ovarian
cancer for carriers of one of the four BRCA1 mutations
was 50.6 years, and the average age at diagnosis for
carriers of one of the four BRCA2 mutations was 59.6
years. Although the average age at diagnosis for BRCA1
carriers was slightly younger than that for noncarriers
( ), the average age at diagnosis for BRCA2 car-P  .55
riers was older than those for noncarriers ( ) andP  .09
BRCA1 carriers ( ).P  .02
Although the selection criteria included the number
of female breast cancer cases diagnosed at !65 years of
age or the number of cases of ovarian cancer, a signif-
icant proportion of families found to harbor a mutation
contained at least one breast cancer case diagnosed at
!36 years of age. Twenty-six (58%) of 45 families with
a case of breast cancer diagnosed at !36 years of age
carried a mutation, compared with only 15 (29%) of
52 families with no case of breast cancer before 36 years
of age (odds ratio 3.4; ). In addition, amongP  .004
the families with no ovarian cancer cases, the frequency
of mutations increased for families containing more than
one breast cancer case diagnosed before 36 years of age
( ). Mutations were present in 8%, 33%, 67%,P  .0012
and 80% of families with totals of zero, one, two, or
three or more (maximum of seven) cases, respectively.
Discussion
French Canadian families containing at least three fe-
male breast cancer cases (!65 years of age), ovarian can-
cer, or male breast cancer were screened for fourBRCA1
and four BRCA2 mutations. A mutation was identified
in 41 of 97 families: 24 families had a BRCA1 mutation,
and 17 families had a BRCA2 mutation. Six of the eight
mutations were identified in 40% of the families and
accounted for 95% of mutations identified in families
with mutations. The BRCA1 C4446T and BRCA2
8765delAG mutations accounted for the majority of mu-
tations identified in the French Canadian cancer families.
Although direct comparisons are difficult because of the
differences in selection criteria and because a partial
screen was performed, the proportion of French Cana-
dian cancer families identified to have mutations is
within the range observed in other studies that used a
comprehensive screen of BRCA1 and/or BRCA2 (re-
viewed in Szabo and King 1997).
Although the predictive models used in this study were
based solely on the screening of four BRCA1 and four
BRCA2 mutations in French Canadian cancer families,
as has been observed elsewhere, BRCA1 mutations were
more likely to be identified in families with one or more
cases of ovarian cancer, and BRCA2 mutations were
more likely to be indentified in families with multiple
cases of female and male breast cancer (Narod et al.
1995; Tonin et al. 1996; Shattuck-Eidens et al. 1997;
Szabo and King 1997). Historically, French Canadian
families typically have been large, and therefore the like-
lihood of identifying multiple cases of breast and ovarian
cancer perhaps may be increased. In addition, previous
studies have also described carriers of mutations in the
breast cancer–susceptibility genes who do not have a
strong family history of breast and/or ovarian cancer
(Tonin et al. 1996; Levy-Lahad et al. 1997; Stratton et
al. 1997).
One individual in each of the two families (486 and
825) in our series was diagnosed with fallopian tube
cancer, and in both cases a mutation was identified.
Cases of fallopian tube cancer have been reported in
individuals who were found to be carriers of germ-line
mutations (Simard et al. 1994; Tonin et al. 1996; Schu-
bert et al. 1997). Although in this study the association
of fallopian tube cancers and gene carriers is not statis-
tically significant ( ), the pathological similarityP  .12
to ovarian cancers and the familial association with
other primary cancers, such as breast cancer (Podratz et
al. 1986; Simard et al. 1994; Tonin et al. 1996; Schubert
et al. 1997), warrant further study, to determine whether
germ-line mutations in the breast cancer–susceptibility
genes confer an increased risk for fallopian tube cancers.
Carriers of the most common mutations (C4446T and
8765delAG) in the French Canadian families were found
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Table 5
Frequencies of Breast and Ovarian Cancer Cases and of BRCA1 and BRCA2 Mutations, in French Canadian Families
No. of
Female Breast
Cancers/Family
No. of
Ovarian
Cancers/Family
Total No. of Families
(No. of Families with
Male Breast Cancer)
[ ]n  97
Total No. (%) of Fami-
lies with Mutations
[ ]n  41
No. of Families with a
BRCA1 Mutation
[ ]n  24
No. of Families with a
BRCA2 Mutation
[ ]n  17
2 0 1 (1) 0 0 0
3 0 15 (1) 3 (20) 1 2
4 0 12 2 (17) 1 1
5 0 20 (4) 9 (45) 0 9
2 1 12 4 (33) 3 1
3 1 10 (1) 5 (50) 5 0
4 1 6 4 (67) 3 1
5 1 5 3 (60) 2 1
1 2 3 1 (33) 1 0
2 2 3 1 (33) 1 0
3 2 4 3 (75) 1 2
4 2 3 3 (100) 3 0
5 2 3 (1) 3 (100) 3 0
to share identical or similar haplotypes, providing evi-
dence that disease alleles are identical by descent. The
birthplaces of the grandparents of the mutation carriers
were determined (fig. 1). The birthplaces of the grand-
parents of the carriers with the most common mutations
overlap and have been found predominantly in the
southern part of the province of Quebec. The founders
who settled in Quebec before 1680 have been estimated
to account for approximately two-thirds of the present
French Canadian gene pool in Quebec (Charbonneau et
al. 1987). This geographic region of early settlement
overlaps the areas in which families with the most com-
mon mutations have been found (fig. 1). The two most
common mutations are likely to have been introduced
early in the settlement of Quebec. Carriers of the less
common mutations, which appear to be identical by de-
scent, by haplotype analysis, originated from different
geographic regions within Quebec (fig. 1). The founders
did not contribute uniformly to the contemporary gene
pool, since the contribution observed for some of them
is, in part, the result of a high reproduction rate, com-
pared with that of later immigrants, and also of a dif-
ferent migration pattern (Heyer and Trembley 1995; La-
buda et al. 1997). In addition, the possibility that more
recent immigrants (after 1870) were also carriers of the
same disorders but had different mutations cannot be
ruled out.
Some of the mutations reported in the French Cana-
dian population have been reported in other independent
studies. The C4446T mutation is one of the most com-
mon BRCA1 mutations found in the Breast Cancer In-
formation Core database, and haplotype analysis has
suggested that this mutation may have arisen indepen-
dently at least three times (Neuhausen et al. 1996b). The
haplotype segregating with the C4446T mutation in the
French Canadian families is comparable to that segre-
gating in the two American families reported by Neu-
hausen et al. (1996b). More recently, this mutation was
also identified in two families in France (Stoppa-Lyonnet
et al. 1997). The BRCA2 G6085T mutation has been
reported previously in families from North America
(Phelan et al. 1996) and France (Serova-Sinilnikova et
al. 1997). The genealogy of one of the French Canadian
families carrying the G6085T mutation has revealed or-
igins in the provinces of Aunis and Normandy, in France.
This finding was not surprising, since the majority of
early settlers in Quebec emigrated from these two prov-
inces in France (Charbonneau and Robert 1987). The
BRCA2 6503delTT mutation has been reported in fam-
ilies in England, and British families that carry this mu-
tation have been shown to share intragenic polymor-
phisms (Mazoyer et al. 1996). This BRCA2 mutation
may have been introduced by a carrier who was of Brit-
ish descent, a likely possibility given that the early settlers
in Quebec originated from France and England (Char-
bonneau and Robert 1987). It would be interesting to
determine whether carriers of mutations found in the
French Canadian cancer families shared a common an-
cestry with other families shown to carry identical
mutations.
Variation in risk of breast and ovarian cancer have
been associated with germ-line BRCA2 mutations (Gay-
ther et al. 1997). The analysis of the mutation distri-
bution along the length of the gene indicated a significant
genotype-phenotype correlation, with mutations causing
the highest risk of ovarian cancer relative to breast can-
cer clustered in a region of ∼3.3 kb in exon 11 (Gayther
et al. 1997). Five of the 17 French Canadian families
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Figure 1 Population distribution of BRCA1 and BRCA2 mutations identified in the French Canadian population. Only the southern
region of the province of Quebec, including the Lac St. Jean/Saguenay region and the territory surrounding the St. Lawrence River, is depicted.
Each symbol indicates the location of the grandparental generation of the families that have the BRCA1 mutations C4446T (blackened squares),
2953del3C (blackened circles), 3768insA (blackened triangles), and C2598A (blackened diamonds) and those that have the BRCA2 mutations
8765delAG (grey-shaded squares), 2816insA (grey-shaded circles), G6085T (grey-shaded triangles), and 6503delTT (grey-shaded diamonds).
The arrows with a symbol(s) indicate the location in northern Ontario and in New Brunswick of families with mutations. The divisions within
the province represent catchment areas for each health care center (Centre Local de Services Communautaires).
carrying a BRCA2 mutation had at least one ovarian
cancer case. Two of the three common BRCA2 muta-
tions found in these families occurred outside this “ovar-
ian cancer cluster” region. None of the three families
carrying the G6085T mutation, which is located in the
ovarian cancer cluster region, included cases of ovarian
cancer. Mutations in the distal 3′ end of the BRCA2 gene
in families with breast and ovarian cancer also have been
reported (Hakansson et al. 1997; Serova-Sinilnikova et
al. 1997; Vehmanen et al. 1997).
The French Canadian cancer families examined in this
study were recruited from gynecology and oncology,
breast cancer, and hereditary-cancer clinics and thus rep-
resent a cross section of families that may seek genetic
counseling. Thus, the identification of common muta-
tions in French Canadian breast and ovarian cancer fam-
ilies has important consequences for genetic testing.
Although additional mutations may account for a pro-
portion of the 56 families found not to carry one of the
eight mutations in the screen, a complete genomic screen
of BRCA1 and BRCA2 in the index cases from 14 of
these families (which contained three or more cases of
breast and/or ovarian cancer) has failed to reveal a mu-
tation in either gene (authors’ unpublished data). The
frequency of mutations identified in the French Cana-
dian cancer families is the same as the frequency of mu-
tations found in a recent examination of 220 Ashkenazi
Jewish families (Tonin et al. 1996). However, unlike the
situation for Ashkenazi families, mutations in the
BRCA2 gene accounted for the majority of French Ca-
nadian breast cancer families found to harbor mutations.
Overall, 57% of French Canadian breast/ovarian cancer
families with at least two breast cancer cases and one
ovarian cancer case were found to have a mutation, com-
pared with 73% of Ashkenazi breast/ovarian cancer
families. Mutations were found in a large majority of
both French Canadian and Ashkenazi Jewish families
with at least two cases each of breast cancer and ovarian
cancer. In addition, mutations in BRCA1 were found in
the majority of breast/ovarian cancer families, in both
ethnic groups. However, in contrast to the Ashkenazi
Jewish population, in which the prevalence of carriers
of BRCA1 and BRCA2 mutations is known to be high,
∼2.5% (Struewing et al. 1995a; Oddoux et al. 1996;
Roa et al. 1996), the overall prevalence of carriers of
the mutations identified in the French Canadian popu-
lation is not yet known.
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